Association between Laryngeal Squamous Cell Carcinoma and Polymorphisms in Tumor Necrosis Factor Related Apoptosis Induce Ligand (TRAIL), TRAIL Receptor and sTRAIL Levels

  • Verim, Aysegul (Department of Otorhinolaryngology/Head and Neck Surgery, Haydarpasa Numune Education and Research Hospital) ;
  • Turan, Saime (Department of Molecular Medicine, Istanbul University, Institute of Experimental Medicine) ;
  • Farooqi, Ammad Ahmad (Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College) ;
  • Kahraman, Ozlem Timirci (Department of Molecular Medicine, Istanbul University, Institute of Experimental Medicine) ;
  • Tepe-Karaca, Cigdem (Department of Otorhinolaryngology/Head and Neck Surgery, Haydarpasa Numune Education and Research Hospital) ;
  • Yildiz, Yemliha (Department of Molecular Medicine, Istanbul University, Institute of Experimental Medicine) ;
  • Naiboglu, Baris (Department of Otorhinolaryngology/Head and Neck Surgery, Haydarpasa Numune Education and Research Hospital) ;
  • Ozkan, Nazli Ezgi (Department of Molecular Medicine, Istanbul University, Institute of Experimental Medicine) ;
  • Ergen, Arzu (Department of Molecular Medicine, Istanbul University, Institute of Experimental Medicine) ;
  • Isitmangil, Gulbu Aydinoglu (Laboratory of Immunology, Haydarpasa Numune Education and Research Hospital) ;
  • Yaylim, Ilhan (Department of Molecular Medicine, Istanbul University, Institute of Experimental Medicine)
  • Published : 2015.01.22


The laryngeal squamous cell carcinoma (LSCC) is one of the most common malignant tumors occurring in the head and neck. Tumor necrosis factor related apoptosis induce ligand (TRAIL) and TRAIL-receptors (DR4, DR5, DcR1, DcR2) are known as important members of TRAIL-mediated biochemical signaling pathway. Associations between polymorphisms in these genes and clinicopathological characteristics of human laryngeal carcinoma are not well defined. This study therefore aimed to investigate a possible relationship among the TRAIL and TRAIL-DR4 polymorphisms and sTRAIL levels in the risk or progression of LSCC. A total of 99 patients with laryngeal cancer and 120 healthy subjects were enrolled in the study. DR4 C626G and TRAIL 1595 C/T genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis and sTRAIL levels were measured by ELISA. There were significant differences in the distribution of DR4 C626G genotypes and frequencies of the alleles between laryngeal cancer patients and controls (p<0.001) but not in TRAIL 1595 C/T. We found the increased frequency of the DR4 C626G homozygote CC genotype in patients than in controls (p<0.001). Haplotype analysis revealed that there was also a statistically significant relationship between TRAIL and TRAIL-DR4 polymorphisms and laryngeal cancer. Serum sTRAIL levels in the laryngeal patients with CC genotype who had advanced tumour stage were lower than those of patients with early tumor stage (p=0.014). Our findings suggest that DR4 C626G genotypes and sTRAIL levels might be associated with progression of laryngeal cancer in the Turkish population.


  1. Allen JE, El-Deiry WS (2012). Regulation of the human TRAIL gene. Cancer Biol Ther, 13, 1143-51.
  2. Bisgin A, Kargi A, Yalcin AD et al (2012). Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer, 12, 58.
  3. Braakhuis BJ, Brakenhoff RH, Leemans CR (2012). Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. Ann Oncol, 23, 173-7.
  4. Chen B, Liu S, Wang XL, et al (2009). TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis. Eur J Cancer, 45, 2598-605.
  5. Chen W, Tang WR, Zhang M, Chang K, Wei YL (2014). Association of DR4 (TRAIL-R1) polymorphisms with cancer risk in Caucasians: an updated meta-analysis. Asian Pac J Cancer Prev, 15, 2889-92.
  6. Dechant MJ, Fellenberg J, Scheuerpflug CG, Ewerbeck V, Debatin KM (2004). Mutation analysis of the apoptotic “death-receptors” and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer, 109, 661-7.
  7. den Hollander MW, Gietema JA, de Jong S, et al (2013). Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett, 332, 194-201.
  8. Dobson CL, Main S, Newton P, et al (2009). Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism. MAbs, 1, 552-62.
  9. Fisher MJ, Virmani AK, Wu L, et al (2001). Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res, 7, 1688-97.
  10. Frank B, Hemminki K, Shanmugam KS, et al (2005). Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk. Carcinogenesis, 26, 1975-7.
  11. Frank B, Shanmugam KS, Beckmann L, et al (2006). Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev, 15, 2002-5.
  12. Gray HL, Sorensen EL, Hunt JS, et al (2001). Three polymorphisms in the 3' UTR of the TRAIL (TNFrelated apoptosis-inducing ligand) gene. Genes Immun, 2, 469-70.
  13. Han LH, Sun WS, Ma CH, et al (2002). Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J Gastroenterol, 8, 1077-80.
  14. Hazra A, Chamberlain RM, Grossman HB, et al (2003). Death receptor 4 and bladder cancer risk. Cancer Res, 63, 1157-9.
  15. Heredia-Galvez B, Ruiz-Cosano J, Torres-Moreno D, et al (2014). Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas. Ann Hematol, 93, 243-7.
  16. Horak P, Pils D, Roessler M, et al (2005). Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. Gynecol Oncol, 97, 514-8.
  17. Jablonska E, Jablonski J, Marcinczyk M, et al (2008). The release of soluble forms of TRAIL and DR5 by neutrophils of oral cavity cancer patients. Folia Histochem Cytobiol, 46, 177-83.
  18. Kargi A, Bisgin A, Yalcin AD, et al (2013). Increased serum S-TRAIL level in newly diagnosed stage-IV lung adenocarcinoma but not squamous cell carcinoma is correlated with age and smoking. Asian Pac J Cancer Prev, 14, 4819-22.
  19. Kargi A, Yalcin AD, Erin N, et al (2012). IL8 and serum soluble TRAIL Lev-els following Anti-VEGF monoclonal antibody treat-ment in patients with metastatic colon cancer. Clinical Laboratory, 5-6, 501-5.
  20. Kim H, Ku SY, Suh CS, et al (2012). Association between endometriosis and polymorphisms in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptor and osteoprotegerin genes and their serum levels. Arch Gynecol Obstet, 286, 147-53.
  21. Kim K, Fisher MJ, Xu SQ, et al (2000). Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res, 6, 335-46.
  22. Korner C, Riesner K, Kramer B, et al (2012). TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. BMC Cancer, 12, 85.
  23. Kuraoka K, Matsumura S, Sanada Y, et al (2005). A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. Oncol Rep, 14, 465-70.
  24. Lee SH, Shin MS, Kim HS, et al (1999). Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res, 59, 5683-6.
  25. Lee SH, Shin MS, Kim HS, et al (2001). Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene, 20, 399-403.
  26. Manjarrez ME, Ocadiz R, Valle L, et al (2006). Detection of human papillomavirus and relevant tumor suppressors and oncoproteins in laryngeal tumors. Clin Cancer Res, 12, 6946-51.
  27. Mi YY, Li JM, Shao N, et al (2011). TRAIL gene polymorphism and genetic susceptibility to prostate cancer in the Chinese Han population of Nanjing. Zhonghua Nan Ke Xue, 17, 242-6.
  28. Miller SA, Dykes DD, Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16, 1215.
  29. Oikonomou E, Pintzas A (2013). The TRAIL of oncogenes to apoptosis. Biofactors, 39, 343-54.
  30. Pal R, Gochhait S, Chattopadhyay S, et al (2013). Functional implication of TRAIL-716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor. Breast Cancer Res Treatment, 126, 333-43.
  31. Shi J, Zheng D, Liu Y, et al (2005). Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res, 65, 1687-92.
  32. Tanaka H, Ito T, Kyo T, et al (2007). Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients. Eur J Haematol, 78, 389-98.
  33. Tecchio C, Huber V, Scapini P, et al (2004) IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood, 103, 3837-44.
  34. Teng MS, Brandwein-Gensler MS, Teixeira MS, et al (2005). A study of TRAIL receptors in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg, 131, 407-12.
  35. Wandinger KP, Lunemann JD, Wengert OA, et al (2003). TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet, 361, 2036-43.
  36. Wang C, Xu S, Yi F, et al (2013). Tumor necrosis factor-related apoptosis inducing ligand gene polymorphisms are correlated with gastric cancer. in central China. Pharm Res, [Epub ahead of print]
  37. Wang S (2008). The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene, 27, 6207-15.
  38. Wu F, Hu Y, Long J, et al (2009). Cytotoxicity and radiosensitization effect of TRA-8 on radioresistant human larynx squamous carcinoma cells. Oncol Rep, 21, 461-5.
  39. Xu G, Shi Y (2007). Apoptosis signaling pathways and lymphocyte homeostasis. Cell Res, 17, 759-71.
  40. Yan X, Xu L, Qi J, et al (2009). sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease. Immunogenetics, 61, 551-6.
  41. Yao H, Ji W, Guan C, et al (2006). The expression of tumor necrosis factor related apoptosis induce ligand in human laryngeal squamous cell carcinoma. Lin Chuang Er Bi Yan Hou Ke Za Zhi, 20, 1105-8.
  42. Yao H, Xiao H, Wang C, et al (2011). Apoptosis inducing effect by TRAIL on human laryngeal squamous carcinoma Hep-2 cells. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 25, 127-9.
  43. Yaylim I, Ozkan N, Turan S et al (2012). sTRAIL serum levels and TRAIL 1595 genotypes: associations with progress and prognosis of colorectal carcinoma. J Cancer Therapy, 3, 941-7.
  44. Yildiz R, Benekli M, Buyukberber S, et al (2010). The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer. J Cancer Res Clin Oncol, 136, 1471-6.
  45. Yildiz Y, Yaylim-Eraltan I, Arikan S, et al (2010). Is there any correlation between TNF-related apoptosis-inducing ligand (TRAIL) genetic variants and breast cancer? Arch Med Sci, 6, 932-6.
  46. Yoldas B, Ozer C, Ozen O, et al (2011). Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck, 33, 1278-84.
  47. Yue FE, Liu DY, Song J, et al (2005). Soluble tumor necrosis factor related apoptosis inducing ligand (sTRAIL) and clinical outcome of HBV infection in human. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 19, 146-8.
  48. Zhang M, Zhou L (2009). Synergistic effects and mechanisms of combined tumor necrosis factor-related apoptosis-inducing ligand and chemotherapeutic drugs or radiotherapy in killing laryngeal squamous carcinoma cells in vitro. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 44, 565-70.

Cited by

  1. Modulators of Redox Metabolism in Head and Neck Cancer pp.1557-7716, 2017,
  2. Genetic Variants in the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Death Receptor Genes Contribute to Susceptibility to Bladder Cancer vol.19, pp.6, 2015,
  3. Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer vol.14, pp.1, 2019,